CHF Solutions Announces Launch of Ultrafiltration Program at Heart Hospital at Saint Francis
April 16 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS) today announced that Heart Hospital at
Saint Francis has launched an ultrafiltration program using the
Aquadex FlexFlow® system to assist in the management of fluid
overload in patients following cardiac surgery and in patients
suffering from heart failure.
The Heart Hospital at Saint Francis is part of St Francis Health
Systems based in Tulsa, Oklahoma and provides the Tulsa community
with comprehensive cardiac care, including cardiac surgery and
heart failure. Saint Francis is a Catholic, not-for-profit health
system wholly owned and operated in Tulsa, Oklahoma.
“We are pleased to partner with Heart Hospital at St Francis to
provide the enhanced ultrafiltration capabilities of the Aquadex
FlexFlow system to treat patients in the Tulsa area,” said John
Erb, chairman, president and CEO of CHF Solutions. “This
arrangement further represents our commitment to providing
clinicians with fluid management solutions for their patients.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow system for
aquapheresis therapy. The Aquadex FlexFlow system is
indicated for temporary (up to eight hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and extended (longer than 8 hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's mission is to
predict, measure, and control patient fluid balance through
science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered
in Minneapolis, Minnesota with wholly owned subsidiaries
in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, the capabilities of the Aquadex FlexFlow system to
manage patients with fluid overload.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future
events to differ materially from the forward-looking statements in
this release, including, without limitation, those risk associated
with our ability to execute on our commercial strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, benefits of our products
to patients, our expectations with respect to product development
and commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with
the SEC. Forward-looking statements speak only as of the
date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR
516-222-2560brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024